Thrivent Financial for Lutherans
TCRT icon

Thrivent Financial for Lutherans’s Alaunos Therapeutics TCRT Stock Holding History

Thrivent Financial for Lutherans’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-916
Closed -$735K – 2025
2016
Q4 		$735K Hold
916
– – ﹤0.01% 1312
2016
Q3 		$773K Buy
+916
New +$736K ﹤0.01% 1251

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Thrivent Financial for Lutherans's TCRT Position: Q1 2017 in Review

Thrivent Financial for Lutherans sold out of Alaunos Therapeutics (TCRT) in Q1 2017, closing a stake of 916 shares — an estimated $735K sold.

Thrivent Financial for Lutherans first reported a position in TCRT in Q3 2016 and held it in 2 quarters. The position peaked at $773K in Q3 2016. 124 funds tracked by Wall St. Rank hold TCRT as of Q1 2017.

  • Thrivent Financial for Lutherans reported no remaining Alaunos Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 916 Alaunos Therapeutics shares in Q1 2017, an estimated $735K.
  • Thrivent Financial for Lutherans first reported a position in Alaunos Therapeutics in Q3 2016 and held it in 2 quarters.
  • Thrivent Financial for Lutherans's Alaunos Therapeutics position peaked at $773K in Q3 2016.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2017.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2017, filed 12 May 2017.